Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Avita Medical Inc. (NASDAQ:RCEL) have received an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.40.

RCEL has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Avita Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Lake Street Capital cut their price target on shares of Avita Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 11th. D. Boral Capital cut their price target on shares of Avita Medical from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, BTIG Research lowered shares of Avita Medical from a “neutral” rating to a “sell” rating and set a $3.00 price target on the stock. in a report on Friday, August 8th.

Avita Medical Price Performance

NASDAQ:RCEL opened at $4.29 on Wednesday. The firm has a market cap of $114.20 million, a price-to-earnings ratio of -2.18 and a beta of 1.58. The company has a current ratio of 0.58, a quick ratio of 0.46 and a debt-to-equity ratio of 9.39. The company’s 50-day moving average is $5.25 and its two-hundred day moving average is $7.03. Avita Medical has a 12-month low of $3.60 and a 12-month high of $14.16.

Avita Medical (NASDAQ:RCEL) last released its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.12). The firm had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $34.27 million. Avita Medical had a negative net margin of 68.87% and a negative return on equity of 632.62%. Avita Medical has set its FY 2025 guidance at EPS. Research analysts expect that Avita Medical will post -0.95 EPS for the current year.

Insider Buying and Selling

In other Avita Medical news, Director Robert Mcnamara purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The shares were purchased at an average price of $4.50 per share, for a total transaction of $45,000.00. Following the completion of the acquisition, the director owned 86,771 shares of the company’s stock, valued at approximately $390,469.50. This represents a 13.03% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased a total of 24,000 shares of company stock valued at $113,660 in the last 90 days. Company insiders own 2.80% of the company’s stock.

Institutional Trading of Avita Medical

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of Avita Medical during the fourth quarter valued at approximately $38,000. CWM LLC grew its position in shares of Avita Medical by 1,099.5% during the first quarter. CWM LLC now owns 4,918 shares of the company’s stock worth $40,000 after buying an additional 4,508 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Avita Medical by 688.9% during the first quarter. GAMMA Investing LLC now owns 6,374 shares of the company’s stock worth $52,000 after buying an additional 5,566 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Avita Medical during the first quarter worth approximately $53,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Avita Medical in the second quarter worth $58,000. Hedge funds and other institutional investors own 27.66% of the company’s stock.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.